Literature DB >> 18607842

Acute aortic dissection in a hypertensive patient with prostate cancer undergoing chemotherapy containing bevacizumab.

Jeanny B Aragon-Ching1, Yang-Min Ning, William L Dahut.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18607842      PMCID： PMC7217319          DOI： 10.1080/02841860801978905

Source DB:  PubMed          Journal:  Acta Oncol        ISSN： 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  5 in total

1.  The International Registry of Acute Aortic Dissection (IRAD): new insights into an old disease.

Authors:  P G Hagan; C A Nienaber; E M Isselbacher; D Bruckman; D J Karavite; P L Russman; A Evangelista; R Fattori; T Suzuki; J K Oh; A G Moore; J F Malouf; L A Pape; C Gaca; U Sechtem; S Lenferink; H J Deutsch; H Diedrichs; J Marcos y Robles; A Llovet; D Gilon; S K Das; W F Armstrong; G M Deeb; K A Eagle
Journal:  JAMA       Date:  2000-02-16       Impact factor: 56.272

Review 2.  Diagnostic imaging in the evaluation of suspected aortic dissection. Old standards and new directions.

Authors:  J E Cigarroa; E M Isselbacher; R W DeSanctis; K A Eagle
Journal:  N Engl J Med       Date:  1993-01-07       Impact factor: 91.245

3.  Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

Authors:  Fairooz F Kabbinavar; Joseph Schulz; Michael McCleod; Taral Patel; John T Hamm; J Randolph Hecht; Robert Mass; Brent Perrou; Betty Nelson; William F Novotny
Journal:  J Clin Oncol       Date:  2005-02-28       Impact factor: 44.544

Review 4.  Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.

Authors:  Xiaolei Zhu; Shenhong Wu; William L Dahut; Chirag R Parikh
Journal:  Am J Kidney Dis       Date:  2007-02       Impact factor: 8.860

Review 5.  Bevacizumab in the management of solid tumors.

Authors:  Roy L Pañares; Agustin A Garcia
Journal:  Expert Rev Anticancer Ther       Date:  2007-04       Impact factor: 4.512
  5 in total
  5 in total

1.  Aortic dissection after ramucirumab infusion.

Authors:  Davide Zenoni; Flavio Niccolò Beretta; Vanessa Martinelli; Alessandro Iaculli; Maria Teresa Benzoni Fratelli; Delia Bonzi
Journal:  Eur J Hosp Pharm       Date:  2019-06-14

Review 2.  Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review.

Authors:  Dorothy Keefe; Joanne Bowen; Rachel Gibson; Thean Tan; Meena Okera; Andrea Stringer
Journal:  Oncologist       Date:  2011-03-25

3.  Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study.

Authors:  Adam Goldman; David Bomze; Rachel Dankner; Dana Fourey; Ben Boursi; Michael Arad; Elad Maor
Journal:  Target Oncol       Date:  2021-05-10       Impact factor: 4.493

4.  Aneurysm and Artery Dissection Following the Use of Vascular Endothelial Growth Factor Inhibitor: A Real-World Analysis Using a Spontaneous Reporting System.

Authors:  Shuyue Wang; Mingzhu Chen; Xinghui Zhang; Lingjian Zhang; Min Jia; Zhiwen Shen; Junyan Wang; Bin Zhao; Yang Gong; Jian Gong
Journal:  J Am Heart Assoc       Date:  2021-11-30       Impact factor: 6.106

5.  Aortic dissection in a patient treated with anlotinib for metastatic lung squamous cell carcinoma.

Authors:  Bailing Jiang; Junhe Li; Jun Chen; Xiaojun Xiang; Jianping Xiong; Jun Deng
Journal:  Thorac Cancer       Date:  2019-12-31       Impact factor: 3.500
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.